CorMedix Reports Q3 2026 Revenue of $54.5 Million and Net Loss of $14.7 Million

CorMedix reported third-quarter 2026 consolidated revenue and grant income of $54.5 million, down from $104.3 million a year earlier, and a net loss of $14.7 million. Adjusted EBITDA was $3.1 million. The company maintained its full-year revenue outlook and narrowed its adjusted EBITDA guidance.Fin…